Skye Bioscience SKYE

Drug Manufacturers - General, Healthcare

$1.54

−4.94%

Market cap: $6.8M
PE: n/m; a loss over the last year
Forward PE: n/m; not a meaningful number
Price to sales: n/m; not a meaningful number
EV/EBIT: n/m; a loss over the last year
Revenue, 12 months: n/m; not a meaningful number
Net margin: n/m; not a meaningful number
Free cash flow yield: −569.2%

Skye Bioscience's trailing earnings are negative, so it has no PE.

Charts

Financials

Income statement for SKYE, by quarter
Income statement	Q3 FY23	Q4 FY23	Q1 FY24	Q2 FY24	Q3 FY24	Q4 FY24	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
R&D	$1.3M−30%	$1.6M+4%	$1.9M+64%	$4.1M+128%	$4.9M+289%	$7.8M+390%	$7.2M+270%	$14.3M+252%	$9.4M+92%	$11.5M+47%	$7.9M+10%	$3.9M−73%
SG&A	$2.2M+96%	$2.5M+62%	$4.2M+120%	$4.3M+259%	$4.6M+108%	$4.6M+83%	$4.6M+9%	$3.9M−10%	$3.9M−16%	$3.4M−25%	$4.7M+4%	$3.9M−1%
	−$24.7M+745%	−$4.1M−56%	−$6.2M+98%	−$8.4M+196%	−$5M−80%	−$10.7M+161%	−$11.8M+91%	−$18.2M+117%	−$13.3M+167%	−$14.9M+40%	−$12.7M+8%	−$11.1M−39%
Interest expense	$271.3K+28%	$430.1K+768%	$436.9K+2275%	$450.1K+141%	−$90.8K	−$46.9K	$1.5K−100%	$0	$0	$0	$2.2K+51%	$3.3K
Pre-tax income	−$24.9M+698%	−$4.4M−55%	−$5M−3%	−$7.9M+154%	−$3.9M−84%	−$9.7M+121%	−$11.1M+121%	−$17.6M+123%	−$12.8M+227%	−$14.4M+48%	−$12.5M+13%	−$10.8M−39%
	$0	$0	$2K	$8.1K+124%	$0	$0	$2K+0%	$3.4K−58%	$0	$0	$0	$3.4K+0%
Net income	−$24.9M+698%	−$4.4M−55%	−$5M−3%	−$7.9M+154%	−$3.9M−84%	−$9.7M+121%	−$11.1M+121%	−$17.6M+123%	−$12.8M+227%	−$14.4M+48%	−$12.5M+13%	−$10.8M−39%
	−$25.36+101%	−$2.88−89%	−$1.44−87%	−$1.60−75%	−$0.80−97%	−$1.92−33%	−$2.24+56%	−$3.52+120%	−$2.56+220%	−$2.88+50%	−$2.56+14%	−$2.16−39%
	985.1K+297%	1.5M+322%	3.5M+643%	4.8M+895%	4.9M+393%	5M+224%	5M+42%	5M+3%	5M+2%	5M−1%	5M+0%	5M+0%

SG&A: Q1 FY13: 6 months less the 3 months printed beside them.

Operating income: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.

Interest expense: Q1 FY13: 6 months less the 3 months printed beside them.

Pre-tax income: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.

Income tax: Q1 FY13: 6 months less the 3 months printed beside them.

Net income: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.

EPS, diluted: 17 periods, Q1 FY12 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY12 and Q1 FY13: share-days: the 6-month average less the second quarter's. Q4 FY12 and Q4 FY19: share-days: the 12-month average less the 9-month, weighted by days. 13 periods, Q4 FY13 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Healthcare nearest Skye Bioscience's size, closest first.

Company	Market cap	PE	Its 10y median PE	P/S	Revenue growth	Net margin
SKYESkye Bioscience	$6.8M	n/m	n/a	n/m	n/m	n/m
NEPHNephros	$38.3M	22.1×	28.4×	1.9×	+24%	8.4%
ATNMActinium Pharmaceuticals	$47.8M	4.2×	3.1×	n/m	n/m	n/m
APTAlpha Pro Tech	$56.7M	13.6×	14.8×	0.9×	+6%	6.8%
SPROSpero Therapeutics	$64.6M	10.1×	9.5×	1.4×	−3%	15.7%
Peer median	$52.3M	11.8×	12.1×	1.4×	+6%	8.4%